Eli Lilly Set to Make €15 Billion Offer for French Biotech Abivax, Report Says
Eli Lilly, one of the world’s biggest pharmaceutical companies, is reportedly preparing a €15 billion offer to acquire the French biotechnology firm Abivax SA, according to recent market reports. This potential deal reflects a strategic push by Eli Lilly to expand its presence in the biotech sector, tapping into cutting‑edge research and development pipelines that could drive future growth. The news has sparked interest from investors, analysts, and the broader stock market, as large‑scale acquisitions often reshape industry dynamics and can influence stock valuations.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
